AI

Nvidia Launches Cosmos 3 Edge AI Model, Expands Japan Partnerships

The chipmaker unveils a world model for robotics and vision systems while building a coalition with Fujitsu, Hitachi, and pharmaceutical giants.

Omega Editorial· July 16, 2026· 2 min read

Nvidia has introduced Cosmos 3 Edge, a new AI model designed to help robots and vision systems perceive and navigate physical environments in real time, as the company deepens its push into Japan's industrial and healthcare sectors.

The model represents Nvidia's latest entry in the world model category—systems capable of learning from a broader range of inputs than traditional large language models. Cosmos 3 Edge follows the May release of Cosmos 3 and targets applications in robotics and autonomous systems that must interact with the physical world.

Building a physical AI coalition in Japan

CEO Jensen Huang announced the expansion during a two-day visit to Japan, where Nvidia is forming a coalition that includes Fujitsu, Hitachi, and Kawasaki Heavy Industries. The partnerships aim to advance what Nvidia calls "physical AI"—systems that can operate in manufacturing, logistics, and industrial environments.

Japan's AI market is projected to reach $27.9 billion by 2029, according to the International Trade Administration. The growth is driven by government initiatives promoting AI adoption and the willingness of Japanese firms to pursue international partnerships.

Nvidia's move follows Microsoft's $10 billion investment in Japan earlier this year, which focused on AI infrastructure and cybersecurity. SoftBank has also pursued partnerships with Microsoft and Sakura Internet to develop AI capabilities in the country.

Healthcare and drug discovery initiatives

Beyond industrial automation, Nvidia is expanding into Japan's pharmaceutical sector through its BioNeMo Agent Toolkit, a platform for autonomous AI drug discovery. The company highlighted the growth of Tokyo-1, an AI drug discovery consortium operated by Xeureka, a Mitsui subsidiary, which has expanded since its 2023 launch.

Major Japanese drugmakers including Astellas Pharma, Daiichi Sankyo, and Ono Pharmaceutical are using Nvidia's biology toolkit to accelerate their research workflows. The company is also partnering with Kawasaki Heavy Industries on industrial automation projects.

Why it matters

Nvidia's Japan expansion signals a strategic shift toward physical AI applications beyond data center chips and cloud-based models. By partnering with established industrial and pharmaceutical companies, Nvidia is positioning its technology for manufacturing, robotics, and life sciences—sectors where Japan maintains significant global expertise. The partnerships also reflect intensifying competition among U.S. tech firms to establish AI footholds in Asia's third-largest economy.

These details were first reported by CNBC.

#nvidia#physical ai#world models#japan ai market#drug discovery#robotics

This is an original analysis by the Omega editorial team. Source reporting: AI Watch.

Want systems like this working for your business?

Book a Call

More in AI

AI· 3 min read

TSMC Lifts 2026 Capex to $64B Despite Stock Decline

The chipmaker's record quarter and bullish AI outlook couldn't prevent a 4% premarket drop as investors took profits.

Via AI Watch · Jul 16, 2026
AI· 3 min read

Japan Launches National AI Infrastructure for Physical AI

NVIDIA and Noetra will build a 140-megawatt AI factory to train multimodal foundation models for robotics, manufacturing, and industrial applications.

Via AI Watch · Jul 16, 2026
AI· 3 min read

Google Cloud partners with Parag Agrawal's $2B AI search startup

Parallel Web Systems will provide web search capabilities to Google's enterprise customers building AI agents with Gemini.

Via AI Watch · Jul 16, 2026